Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

1. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease

Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Heart Actions . 2021 Jan 8;heartjnl-2020-318251. doi: 10.1136/heartjnl-2020-318251. Online ahead of print. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease , , , , , , , Affiliations Expand Affiliations 1 Population Health Research Institute, McMaster University and Hamilton

2021 EvidenceUpdates

2. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Circulation Actions . 2021 Feb 2;143(5):438-448. doi: 10.1161/CIRCULATIONAHA.120.051675. Epub 2020 Nov 13. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

2021 EvidenceUpdates

3. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Renal Medicine, University College London, London, UK; The George Institute for Global Health

2021 EvidenceUpdates

4. Somethin’ Fishy: Prescription variants of Omega-3 to prevent cardiovascular disease

Somethin’ Fishy: Prescription variants of Omega-3 to prevent cardiovascular disease November 16, 2020 Somethin’ Fishy: Prescription variants of Omega-3 to prevent cardiovascular disease Clinical Question: Do prescription variants of omega-3’s, like icosapent, reduce the risk of cardiovascular events when added to statins? Bottom Line: In high risk patients, icosapent reduced cardiovascular events to 17% from 22% on placebo after 5 years. In lower risk patients, Eicosapentaenoic Acid (EPA) ethyl (...) of cardiovascular disease 4,5 particularly when examining high quality studies. 5 • Evidence gaps include: o A small secondary prevention trial has not been published. 6 o Additional trials evaluating EPA on cardiovascular outcomes are not being conducted. 7 o No studies compare EPA products. o Concerns exist with approving medications on single trial results. 8 • Only icosapent is approved in Canada. 9 o Cost (~$3600/year) requires >40% reduction to approach cost effectiveness. 10 Authors: Allison Paige MD

2021 Tools for Practice

5. What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases?

What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases? I WHO HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 71 What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases? Christian Ulrich Eriksen | Oxana Rotar | Ulla Toft | Torben JørgensenThe Health Evidence Network The Health Evidence Network (HEN) is an information service for public health decision (...) for Europe has three main functions: leading the integrated response of policies to address noncommunicable diseases (NCDs) at the regional and country levels; managing the major NCDs (cardiovascular diseases, cancer, chronic respiratory diseases and diabetes) across the continuum of care from prevention to early detection, screening, diagnosis, treatment, rehabilitation, secondary prevention and end-of-life/palliative care; and leading the NCD health systems response. It focuses on priority action areas

2021 WHO Health Evidence Network

6. Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality

Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) . Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality , , , , , , , , Affiliations Expand Affiliations 1 Department of Preventive Medicine, Northwestern University, Chicago, Illinois; Department of Pediatrics, Northwestern University, Chicago, Illinois. Electronic address: amarma@luriechildrens.org. 2 Department of Preventive Medicine, Northwestern University, Chicago, Illinois. 3 Department of Preventive Medicine, Northwestern University

2021 EvidenceUpdates

7. Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Behavioral Counseling Interventions

Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Behavioral Counseling Interventions Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults who are overweight or obese and have additional CVD risk factors The USPSTF recommends offering or referring adults who (...) are overweight or obese and have additional cardiovascular disease (CVD) risk factors to intensive behavioral counseling interventions to promote a healthful diet and physical activity for CVD prevention. B View the Clinical Summary in Population Adults in primary care who are overweight or obese and have known cardiovascular risk factors Recommendation Offer or refer to intensive behavioral counseling interventions to promote a healthful diet and physical activity. Grade: B Risk Assessment Well-established

2020 U.S. Preventive Services Task Force

8. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search December 2020 November 2020 October 2020 September 2020 August 2020 July (...) 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association , PhD, MPH, FAHA, Chair , EdD, MS, FAHA , PhD, FAHA , MD, FAHA , MD, MS, MBA , MD, MPH, FAHA , MD, FAHA

2020 American Heart Association

9. Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM Full Text available with Trip Pro

. (EARL) has established a standard ( , ) for intercenter harmonization for [ 18 F]FDG imaging. A standard for PET/CT imaging in inflammatory, infective, infiltrative, and innervation dysfunctional (4Is) cardiovascular diseases is currently lacking. Therefore, standards for PET imaging not limited to FDG are needed specifically designed for cardiovascular disorders. Goals The purpose of this document is to assist in performing PET/CT and PET/MR for cardiovascular imaging in the field of 4Is, starting (...) Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM | SpringerLink Search Search SpringerLink Search Procedural

2020 European Association of Nuclear Medicine

10. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, Department of Internal Medicine, University

2020 EvidenceUpdates

11. Association of beta-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis Full Text available with Trip Pro

Association of beta-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard (...) Share Permalink Copy Page navigation Eur Heart J Actions . 2020 Nov 19;ehaa793. doi: 10.1093/eurheartj/ehaa793. Online ahead of print. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union

2020 EvidenceUpdates

12. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Full Text available with Trip Pro

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Departamento de Medicina Preventiva, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, n° 740, Vila Clementino, São Paulo, SP CEP 04023-062 Brazil. 2 Sociedade Brasileira de Diabetes-SBD, Rua Afonso Braz, 579, Salas 72/74, Vila Nova Conceição, São Paulo, SP CEP 04511-011 Brazil. 3 Programa de Pós-Graduação Em Endocrinologia

2020 EvidenceUpdates

13. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Full Text available with Trip Pro

Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study - PubMed This site needs JavaScript (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 7. doi: 10.1111/dom.14189. Online ahead of print. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Oslo

2020 EvidenceUpdates

14. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. Full Text available with Trip Pro

plots and tabular presentations was performed. Associations for composite cardiovascular disease were: twofold for pre-eclampsia, stillbirth, and preterm birth; 1.5-1.9-fold for gestational hypertension, placental abruption, gestational diabetes, and premature ovarian insufficiency; and less than 1.5-fold for early menarche, polycystic ovary syndrome, ever parity, and early menopause. A longer length of breastfeeding was associated with a reduced risk of cardiovascular disease. The associations (...) contraceptives or progesterone only pill), pre-eclampsia, and recurrent pre-eclampsia; 1.5-1.9-fold for current use of combined oral contraceptives, gestational diabetes, and preterm birth; and less than 1.5-fold for polycystic ovary syndrome. The association for heart failure was fourfold for pre-eclampsia. No association was found between cardiovascular disease outcomes and current use of progesterone only contraceptives, use of non-oral hormonal contraceptive agents, or fertility treatment.From menarche

2020 BMJ

15. Thyroid Dysfunction and cardiovascular events in patients with chronic kidney disease: A protocol of systematic review and meta-analysis Full Text available with Trip Pro

Thyroid Dysfunction and cardiovascular events in patients with chronic kidney disease: A protocol of systematic review and meta-analysis Inplasy Protocol 856 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

16. Findings on the relationship between cardiovascular disease and coronavirus disease 2019: a systematic review Full Text available with Trip Pro

in the elderly, immunosuppressed, and those with cardiovascular comorbidities. Therefore, a better understanding of these findings is needed. A systematic review was carried out looking for articles published between December 2019 and May 2020 on the MEDLINE / PubMed search platform using the following descriptors : ((((((((("cardiovascular disease") OR ("acute myocardial infarction")) OR ("coronary artery disease")) OR ("acute coronary syndrome")) OR ("atherosclerosis")) OR ("cardiac insufficiency (...) , immunosuppressed, and those with cardiovascular comorbidities. Therefore, a better understanding of these findings is needed. A systematic review was carried out looking for articles published between December 2019 and May 2020 on the MEDLINE / PubMed search platform using the following descriptors : ((((((((("cardiovascular disease") OR ("acute myocardial infarction")) OR ("coronary artery disease")) OR ("acute coronary syndrome")) OR ("atherosclerosis")) OR ("cardiac insufficiency")) OR ("pericarditis

2020 Research Square

17. Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis

Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) ahead of print. Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis # , # , , , Affiliations Expand Affiliations 1 Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece. 2 School of Medicine, European University of Cyprus, Nicosia, Cyprus. 3 Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. 4 Clinical

2020 EvidenceUpdates

18. Cost-effectiveness of cardiovascular imaging for stable coronary heart disease Full Text available with Trip Pro

Cost-effectiveness of cardiovascular imaging for stable coronary heart disease Cost-effectiveness of cardiovascular imaging for stable coronary heart disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Heart Actions . 2020 Aug 14;heartjnl-2020-316990. doi: 10.1136/heartjnl-2020-316990. Online ahead of print. Cost-effectiveness of cardiovascular imaging for stable coronary heart disease

2020 EvidenceUpdates

19. Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS

Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS Report available at https://muhc.ca/tau Technology Assessment Unit of the McGill University Health Centre (MUHC) Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS Report number: 84 DATE: May 14 th , 2020 Report available at https://muhc.ca/tau Report prepared (...) cardiovascular disease at the MUHC RUISSS. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2020 May 14. Report no. 84. 64 pagesApoB iii 14 May 2020 Technology Assessment Unit, MUHC ACKNOWLEDGEMENTS The expert assistance of the following individuals is gratefully acknowledged: ? David Blank, MUHC Site Chief, Division of Biochemistry, Department of Clinical Laboratory Medicine, MUHC ? Allan Sniderman, Cardiologist at the MUHC and Senior Scientist

2020 McGill TAU reports

20. Comparison of the cardiorenal benefits from SGLT2 inhibitors for patients with different underlying disease: a meta-analysis of cardiovascular and renal outcome trials Full Text available with Trip Pro

Comparison of the cardiorenal benefits from SGLT2 inhibitors for patients with different underlying disease: a meta-analysis of cardiovascular and renal outcome trials Inplasy Protocol 819 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols